RBC Looks For Post-Approval Data On MannKind

Shares of MannKind MNKD have traded up as much as 11 percent Monday, following Friday's announcement by the company that AFREZZA has received FDA approval.

In response to the announcement, RBC Capital released a note stating that the next key catalysts the firm sees are post-approval data and a partnership, which the firm views as "likely."

Shares of Mannking are currently trading at $11.01, up 10.1 percent.